Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Drug Safety
Published in: Drug Safety 14/2002

01-12-2002 | Original Research Article

Assessing the Feasibility of Using an Adverse Drug Reaction Preventability Scale in Clinical Practice

A Study in a French Emergency Department

Authors: Pascale Olivier, Olivier Boulbés, Marie Tubery, Dominique Lauque, Jean-Louis Montastruc, Dr Maryse Lapeyre-Mestre

Published in: Drug Safety | Issue 14/2002

Login to get access

Abstract

Objective: To assess the preventability of adverse drug reactions (ADRs) leading to hospital admissions and to investigate the feasibility of the use of a standardised preventability scale in clinical practice.
Design: The study was a prospective pharmacovigilance study. All patients more than 15 years old admitted to an emergency department during a period of 4 weeks were included. Characteristics of patients admitted for a suspected ADR (cases) were compared to those admitted for other reasons (controls). Preventability was assessed in two different ways: (i) by using a standardised preventability scale; and (ii) by the assessment of four reviewers without the scale. Results of the two methods were compared.
Patients: In total, 671 patients were admitted to an emergency department during the study period.
Results: Overall, 44 ADRs were identified involving 41 patients. The incidence of hospital admissions for ADRs was 6.1 per 100 admissions (95% CI 4.4–8.3). According to the French causality assessment method, 71% of ADRs were ‘possible’, 18% were ‘plausible’ and 11% were ‘likely’. Using the standardised preventability scale, one-third of all ADRs were considered as being preventable (9% ‘definitely’ and 25% ‘potentially’ preventable). Reviewers found that 54.5% of ADRs were ‘preventable’. Discrepancies between the two methods concerned mainly cases defined as not preventable by the scale. In general, reviewers overestimated the preventability of ADR compared with the scale.
Conclusions: These results emphasise that ADRs leading to hospitalisation are frequent, with one-third of them likely to be preventable. Moreover, the risk of ADRs mainly involved a small number of drugs. Our experience suggests that there is a need for further studies to validate the French standardised scale of preventability assessment.
Literature
1.
Classen DC, Pestotnik SL, Evans RS, et al. Adverse drug events in hospitalized patients: excess lenght of stay, extra costs and attribuable mortality. JAMA 1997; 277(4): 301–6PubMedCrossRef
2.
Hallas J, Harvald B, Gram LF, et al. Drug related hospital admissions: the role of definitions and intensity of data collection. J Intern Med 1990; 228: 83–90PubMedCrossRef
3.
Detournay B, Fagnani F, Pouyanne P, et al. Cost of hospitalizations related to side-effects of drugs. Therapie 2000; 55: 137–9PubMed
4.
Einarson TR. Drug related hospital admissions. Ann Pharmacother 1993; 27: 832–40PubMed
5.
Imbs JL, Pouyanne P, Haramburu F, et al. Iatrogénie médicamenteuse: estimation de sa prévalence dans les hôpitaux publics français. Therapie 1999; 54: 21–7PubMed
6.
Pouyanne P, Haramburu F, Imbs JL, et al. Admissions to hospital caused by adverse drug reactions: cross sectional incidence study [letter]. BMJ 2000; 320: 1036PubMedCrossRef
7.
Letrilliart L, Hanslik T, Biour M, et al. Postdischarge adverse drug reactions in primary care originating from hospial care in France: a nationwide prospective study. Drug Saf 2001; 24(10): 781–92PubMedCrossRef
8.
Lagnaoui R, Moore N, Fach J, et al. Adverse drug reactions in a department of systemic diseases-oriented internal medicine: prevalence, incidence, direct costs and avoidability. Eur J Clin Pharmacol 2000; 55: 181–6CrossRef
9.
Pearson TF, Pittman DG, Longley JM, et al. Factors associated with preventable adverse drug reactions. Am J Hosp Pharm 1994; 51: 2268–72PubMed
10.
Bates DW, Cullen DJ, Laird N, et al. Incidence of adverse drug events and potential adverse drug events: implications for prevention. JAMA 1995; 274: 29–34PubMedCrossRef
11.
Dartnell JGA, Anderson RP, Chohan V, et al. Hospitalisation for adverse events related to drug therapy: incidence, avoidability and costs. Med J Aust 1996; 164: 659–62PubMed
12.
Petersen LA, Brennan TA, O’Neil AC, et al. Does housestaff discontinuity of care increase the risk for preventable adverse events? Ann Intern Med 1994; 121: 866–72PubMed
13.
Raschetti R, Morgutti M, Menniti-Ippolito F, et al. Suspected adverse drug events requiring emergency department visits or hospital of admissions. Eur Clin J Pharmacol 1999; 54: 959–63CrossRef
14.
Schumock GT, Thornton JP. Focusing on preventability of adverse drug reactions [letter]. Hosp Pharm 1992; 27: 538PubMed
15.
Imbs JL, Pletan Y, Spriet A, et al. Evaluation de la iatrogénèse médicamenteuse évitable: méthodologie. Therapie 1998; 53: 365–70PubMed
16.
World Health Organization. Collaborating centers for international drug monitoring. WHO publication DEM/NC/ 84.153 (E). Geneva: WHO, 1984
17.
Organisation Mandiale de la Santos. Classification Internationale des Maladies, geme revision(ICD-9). Geneva, Switzerland, 1977
18.
Anatomical therapeutic chemical (ATC) classification index, Geneva: WHO Collaborating Center for Drug Statistics Methodology, 1992
19.
Bégaud B. Dictionary of pharmacoepidemiology. ARME-Pharmacovigilance. New York; John Wiley & Sons Ltd, 2000
20.
Bégaud B, Evreux JC, Jouglard J, et al. Unexpected or toxic drug reaction assessment (imputation): actualization of the method used in France. Therapie 1985; 40: 115–8
21.
Hallas J, Gram LF, Grodum E, et al. Drug-related admissions to medical wards: a population base survey. Br J Clin Pharmacol 1992; 33: 61–8PubMedCrossRef
22.
Bongard V, Menard-Tache S, Bagheri H, et al. Perception of the risk of adverse drug reactions: difference between health professionals and non-health professionals. Br J Clin Pharmacol. In press.
Metadata
Title
Assessing the Feasibility of Using an Adverse Drug Reaction Preventability Scale in Clinical Practice
A Study in a French Emergency Department
Authors
Pascale Olivier
Olivier Boulbés
Marie Tubery
Dominique Lauque
Jean-Louis Montastruc
Dr Maryse Lapeyre-Mestre
Publication date
01-12-2002
Publisher
Springer International Publishing
Published in
Drug Safety / Issue 14/2002
Print ISSN: 0114-5916
Electronic ISSN: 1179-1942
DOI
https://doi.org/10.2165/00002018-200225140-00005

Other articles of this Issue 14/2002

Drug Safety 14/2002 Go to the issue

Commentary

Short Course in Pharmacoepidemiology and Pharmacovigilance at the London School of Hygiene and Tropical Medicine

Review Article

Tolerabilities of Antiretrovirals in Paediatric HIV Infection

Review Article

The Use and Safety of Non-Allopathic Indian Medicines

Original Research Article

Gastrointestinal Safety of an Extended-Release, Nondeformable, Oral Dosage Form (OROS®)1

Review Article

Indinavir-Induced Retinoid-Like Effects